Advanced in Testicular Yolk Sac Tumor

Dr. Bradley R. Corr

University Physicians Incorporated
Aurora, CO
Advanced
in Testicular Yolk Sac Tumor
Specialties:Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Bradley Corr is a Gynecologic Oncologist and an Oncologist in Aurora, Colorado. Dr. Corr and is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Bladder Reconstruction, and Hysterectomy. Dr. Corr is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in CO
Hospital Affiliations
Uchealth Highlands Ranch Hospital
University Of Colorado Hospital Authority
St Mary's Regional Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical Campus, Aurora, CO 80045
720-848-0000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Gemcitabine
Study Phase: Phase 1
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Drugs: Docetaxel, PI3Kbeta Inhibitor AZD8186
Study Phase: Phase 1
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Biological, Drug
Study Drugs: Anetumab ravtansine, Bevacizumab, Paclitaxel
Study Phase: Phase 2
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Radiation, Drug
Study Drugs: Atezolizumab, Cisplatin
Study Phase: Phase 1
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2024
Intervention Type: Other, Drug
Study Drugs: Topotecan Hydrochloride, Veliparib
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
Enrollment Status: Terminated
Publish Date: February 20, 2024
Intervention Type: Drug, Radiation
Study Drugs: Adavosertib, Cisplatin
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Enrollment Status: Unknown
Publish Date: April 25, 2022
Intervention Type: Biological
Study Drugs: AVOVA-1, MC
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: September 03, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 20 Less Clinical Trials

43 Total Publications

Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Journal: Gynecologic oncology
Published: December 03, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Saketh R. Guntupalli
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Saketh R. Guntupalli
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Physicians Incorporated

13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
 (0.4 mi)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saketh Guntupalli is a Gynecologic Oncologist and an Oncologist in Aurora, Colorado. Dr. Guntupalli and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Guntupalli is currently accepting new patients.

Kian Behbakht
Expertise in
15
conditions
Dr. Kian Behbakht
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Kian Behbakht
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Physicians Incorporated

1635 Aurora Ct, 
Aurora, CO 
 (0.2 mi)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kian Behbakht is a Gynecologic Oncologist and an Oncologist in Aurora, Colorado. Dr. Behbakht and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Vulvectomy, and Hysterectomy. Dr. Behbakht is currently accepting new patients.

Expertise in
14
conditions
Dr. Jill K. Alldredge
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
14
conditions
Dr. Jill K. Alldredge
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

University Physicians Incorporated

1635 Aurora Ct, 
Aurora, CO 
 (0.2 mi)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jill Alldredge is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Aurora, Colorado. Dr. Alldredge and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, Endometrial Cancer, and Hysterectomy. Dr. Alldredge is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile